title: Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome.
abstract: OBJECTIVE
  The objective of this study were (1) to evaluate the prevalence of anti-annexin II antibodies in patients with various autoimmune diseases and antiphospholipid syndrome and (2) to correlate anti-annexin II antibodies with anti-phospholipid antibodies.
  
  
  METHODS
  Anti-annexin II antibodies and anti-phospholipid were detected, using an enzyme-linked immunosorbent assay, in the serum of patients with primary antiphospholipid syndrome (n = 16), systemic lupus erythematosus (n = 53), primary Sjögren syndrome (n = 71), systemic sclerosis (n = 17), systemic vasculitis (n = 18), and rheumatoid arthritis (n = 119). Healthy blood donors (n = 99) were used as controls.
  
  
  RESULTS
  Anti-annexin II antibodies were significantly more prevalent in patients with connective tissue diseases (8.5%), especially antiphospholipid syndrome (14.8%) and rheumatoid arthritis (10%), than in controls (2%). An inverse correlation was observed between anti-annexin II antibodies and antiphospholipid antibodies.
  
  
  CONCLUSIONS
  Annexin II can be recognized by antibodies in serum from patients with systemic autoimmune disorders. Further studies are required to determine the clinical significance of anti-annexin II antibodies in rheumatoid arthritis and to determine their diagnostic value in discriminating clinical subgroups of patients with antiphospholipid syndrome.
authors.affiliation: Department of Internal Medicine, Amiens University Hospital, 80054 Amiens Cedex 1, France. salle.valery@chu-amiens.fr
authors.forename: V
authors.initials: V
authors.lastname: Salle
authors.forename: J C
authors.initials: JC
authors.lastname: Mazière
authors.forename: A
authors.initials: A
authors.lastname: Smail
authors.forename: R
authors.initials: R
authors.lastname: Cévallos
authors.forename: C
authors.initials: C
authors.lastname: Mazière
authors.forename: V
authors.initials: V
authors.lastname: Fuentes
authors.forename: B
authors.initials: B
authors.lastname: Tramier
authors.forename: R
authors.initials: R
authors.lastname: Makdassi
authors.forename: G
authors.initials: G
authors.lastname: Choukroun
authors.forename: O
authors.initials: O
authors.lastname: Vittecoq
authors.forename: V
authors.initials: V
authors.lastname: Goëb
authors.forename: J P
authors.initials: JP
authors.lastname: Ducroix
mesh_terms: D000328:Adult; D000368:Aged; D017306:Annexin A2 / Q000276:immunology*; D017152:Antibodies, Antiphospholipid / Q000097:blood / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: C472822:ANXA2 protein, human; D017306:Annexin A2; D017152:Antibodies, Antiphospholipid; D001323:Autoantibodies; D001324:Autoantigens